NEP
N-ethylpentedrone
Viewing r1 — Apr 26, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
NEP (N-ethylpentedrone) is an emerging synthetic stimulant of the substituted cathinone class. It is the N-ethyl homolog of pentedrone, distinguished by a substantially longer duration of action. NEP is a presumed norepinephrine-dopamine reuptake inhibitor, producing its effects by blocking the clearance of dopamine and norepinephrine from synapses.[1][2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
cocaine, amphetamine, methamphetamine +2 morecocaine, amphetamine, methamphetamine, pentedrone, n-ethylhexedrone show less
First identified in a European police seizure in 2013,[3] NEP emerged as a designer modification of pentedrone crafted to circumvent existing cathinone scheduling. By the early 2020s it had appeared in dozens of fatal poisoning cases in Poland and a severe ICU admission involving muscle breakdown and kidney failure in Belgium.[4] A 2025 DEA-commissioned study classified its abuse liability as comparable to cocaine and methamphetamine.[5]
Subjective effects include euphoria, psychomotor stimulation, appetite suppression, and increased wakefulness. The experience is a utilitarian stimulant drive — dopaminergic arousal without the empathogenic warmth of serotonin-active cathinones, closer to Cocaine in character than to mephedrone.[6] Anxiety, paranoia, and compulsive redosing are characteristic unsought effects.
NEP carries high dependence liability based on animal and structural evidence, and no lethal dose has been established in any species.[7] Repeated exposure drives molecular changes in the brain's reward circuits that amplify the compulsive redosing urge beyond the pleasure obtained — a pattern characteristic of compulsive stimulant use. No controlled human studies have been published; the current understanding rests on a single case report, one animal study, and structural analogy to related cathinones.
History[edit]
Discovery
NEP was created as a structural modification of pentedrone, replacing the N-methyl group with an N-ethyl substituent to produce a compound not covered by existing cathinone scheduling. No academic publication documents the original synthesis or inventor.citation needed The compound was first identified through a European police seizure in 2013,[3] with detection in the United States following in 2014.citation needed
Proliferation
Through the mid-2010s, NEP circulated as a research chemical sold online, typically appearing as a white crystalline powder.[6][8] By 2022 it ranked among the most frequently detected synthetic cathinones in fatal poisoning cases in Poland, identified in blood samples from 26 fatal and 2 non-fatal cases.[8] Case reports from 2023–2024 documented severe ICU-level toxicity in Belgium[4] and use in a drug-facilitated sexual assault context in France.[6]
Regulatory response
In June 2022, the DEA placed the closely related N-ethylhexedrone and five other synthetic cathinones in Schedule I, but NEP was not included.[9] In June 2025, the European Union Drugs Agency published its formal initial report on NEP through the EU Early Warning System.[3] A DEA-commissioned behavioral study published the same year classified NEP's abuse liability as comparable to cocaine and methamphetamine.[5]
The name NEP derives from N-Ethylpentedrone, following the abbreviated naming convention common among synthetic cathinones. It also appears in forensic literature as NEPD, α-EAPP, and α-ethylaminovalerophenone.[10] NEP has appeared in chemsex settings, where its stimulant profile without entactogenic properties positions it as a utilitarian stimulant rather than a social euphoriant.[6]
Chemistry[edit]
Structural class
NEP belongs to the substituted cathinone family, a subclass of β-keto amphetamines. The cathinone scaffold is modified in NEP by extension of both the α-carbon alkyl chain (propyl, yielding a pentanone backbone) and the terminal amine (N-ethyl rather than N-methyl). NEP is the direct N-ethyl homolog of pentedrone and the α-chain-shortened structural analog of N-ethylhexedrone.
In cathinone structure-activity relationships, the size of the N-alkyl substituent and the α-chain length are the principal determinants of transporter selectivity and whether the compound acts as a reuptake inhibitor or a monoamine releaser.[11][2]
Molecular identity
| Molecular formula | C₁₃H₁₉NO |
| Molecular weight | 205.30 g/mol |
The structure comprises a phenyl ring bonded to a carbonyl group (the β-keto moiety), an α-carbon bearing a propyl chain, and an ethylamino group. Its moderate lipophilicity (XLogP 2.9) predicts adequate blood-brain barrier penetration.[10]
Stereochemistry
NEP possesses one chirality center at C-2, giving rise to (R)- and (S)-enantiomers. Commercially available NEP is presumed racemic mixture. Cathinone derivatives including NEP exhibit chemical and stereochemical instability, particularly at elevated pH.[12]
Chiral separation of both enantiomers and their metabolites has been achieved in biological matrices,[12] but the pharmacological contribution of each isomer remains uncharacterized.
Physical properties
No published data on melting point, aqueous solubility, or solid-state stability specific to NEP have been identified. The compound is typically encountered as a white crystalline powder in forensic seizures.[6]
Pharmacology[edit]
Mechanism of action
NEP is classified as a norepinephrine-dopamine reuptake inhibitor (NDRI) — it blocks the transporters that clear dopamine and norepinephrine from the synapse, increasing their signaling, without causing those transporters to release stored monoamines. This classification rests on structural analogy rather than direct measurement, as no transporter binding or inhibition data for NEP itself have been published.
The inference draws on two reference compounds. Pentedrone, which differs from NEP by only a single carbon at the amine, was characterized as a non-releasing dopamine and norepinephrine uptake inhibitor.[1] N-ethylhexedrone, one additional chain carbon beyond NEP, showed potent dopamine and NET inhibition with negligible SERT activity.[2]
Within the pharmacological classification of designer cathinones — cocaine-like uptake inhibitors, amphetamine-like releasers, and pyrovalerone-like selective DAT/NET inhibitors — NEP falls into the third group by analogy.[13] This predicts strong dopaminergic stimulant effects and elevated addiction liability relative to cathinones with serotonergic activity.[14]
N-ethyl substitution on cathinone backbones augments relative serotonin transporter potency compared to N-methyl while reducing releasing effects — consistent with NEP's non-releasing profile.[15]
Pharmacokinetics
No formal human pharmacokinetic studies have been published. Oral bioavailability, peak plasma time, volume of distribution, protein binding, and half-life are all unknown.
The primary metabolic pathway is N-deethylation, with carbonyl reduction as a secondary route.[16] The specific liver enzymes involved have not been identified, though CYP2D6 and CYP3A4 are suspected by analogy with other N-alkyl cathinones.inferred Key metabolites have been confirmed in human urine following 20–40 mg doses administered intranasally or orally.[17]
The only published plasma persistence data come from a Belgian case report: blood concentrations exceeding 2,000 ng/mL showed no measurable decline over 17 hours after intranasal administration.[4] This suggests an unusually long elimination half-life, but formal pharmacokinetic calculation was not performed.
Detection
NEP shares the metabolite 2-amino-1-phenylpentan-1-ol with Pentedrone and α-PVP, creating challenges for forensic identification.[18] Standard clinical drug screens show poor cross-reactivity with synthetic cathinones including NEP, producing frequent false negatives.[19] Confirmatory identification requires advanced analytical methods such as LC-MS/MS.[17][4]
Neuroscience[edit]
Where it acts
By blocking dopamine reuptake, NEP prolongs dopamine signaling in the nucleus accumbens — the brain's primary reward hub — producing euphoria and motivational drive.[14][20] Simultaneous norepinephrine reuptake inhibitor in cortical and subcortical circuits drives the arousal, alertness, and cardiovascular activation that accompany the stimulant experience.
Repeated NEP exposure in mice produces robust accumulation of ΔFosB in the striatum, a molecular marker that persists for weeks and promotes compulsive drug-seeking.[7] During withdrawal, striatal dopamine drops and stress hormones rise, producing a state consistent with low mood, irritability, and anxiety.[7]
Why it matters
NEP's high selectivity for dopamine over serotonin transporters places it within the incentive salience framework: it preferentially amplifies wanting (the motivational drive to redose) over liking (hedonic pleasure), creating a pattern where the urge to use escalates beyond the reward obtained.[14]
Repeated exposure also produces locomotor sensitization — the brain's progressive amplification of stimulant-driven movement and motivation — while simultaneously depleting baseline dopamine.[7] This dissociation between rising wanting and falling liking is the neurobiological engine of compulsive redosing and binge use.
Key unknowns include whether NEP produces direct damage to dopamine or norepinephrine neurons at recreational doses and how the (R)- and (S)-enantiomers differ in their pharmacological effects. The compound's prolonged plasma persistence — exceeding 17 hours at high concentrations in one case[4] — may reflect slow metabolism, extensive tissue distribution, or continued absorption, a question critical for overdose management.
Subjective Effects[edit]
NEP delivers a focused, utilitarian stimulant experience shaped by its dopamine- and norepinephrine-selective mechanism with negligible serotonin involvement. At lower doses the effect is primarily arousal and concentration; higher doses intensify euphoria and psychomotor activation but sharpen the compulsive compulsive redosing urge, particularly via insufflation. Set and setting modulate the balance between productive stimulation and anxious overstimulation, but the experience lacks the qualitative emotional shifts seen with serotonin-active compounds.[6]
Mechanistically closest to cocaine — pure reuptake inhibitor without monoamine release — but substantially longer-lasting.[13] Compared to mephedrone or methylone, NEP lacks the empathogenic warmth; only a small minority of users report any MDMA-like quality.[6]
Effect Grid
At common doses (approximately 20-40 mg intranasal), the full stimulant profile emerges: pronounced euphoria, significant thought acceleration, strong motivation enhancement, and increased confidence. Focus enhancement is prominent. Compulsive redosing urge becomes a notable feature at this range, consistent with the DAT-dominant mechanism.
Physically, tachycardia is evident, appetite is markedly suppressed, bruxism is common, and excessive sweating may occur. Vasoconstriction produces cold extremities. Duration of stimulation extends for several hours, and sleep is impossible during the active phase.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual processing acceleration · Visual acuity enhancement · Tinnitus · Shadow people
Dry mouth · Insomnia · Pupil dilation · Restlessness · Dehydration sensation · Excessive sweating · Heart rate perception changes · Muscle tension · Physical fatigue · Respiratory stimulation · Spontaneous body sensations · Bruxism · Headache · Tingling / electric sensations · Trembling · Sexual arousal enhancement · Dizziness · Nausea · Tactile euphoria · Vibrations / buzzing · Sexual arousal suppression · Increased urination · Involuntary body movements · Motor control impairment · Nystagmus (eye wobbles) · Vomiting · Tactile hallucination
Restlessness · Dehydration sensation · Excessive sweating · Heart rate perception changes · Muscle tension · Physical fatigue · Respiratory stimulation · Spontaneous body sensations · Bruxism · Headache · Tingling / electric sensations · Trembling · Sexual arousal enhancement · Dizziness · Nausea · Tactile euphoria · Vibrations / buzzing · Sexual arousal suppression · Increased urination · Involuntary body movements · Nystagmus (eye wobbles) · Vomiting · Tactile hallucination
Immersion enhancement · Multiple thought streams · Novelty enhancement · Pattern recognition enhancement · Analysis enhancement · Focus enhancement · Motivation enhancement · Information processing enhancement · Motivation suppression · Aesthetic enhancement · Cognitive dysphoria · Cognitive flexibility · Thought connectivity · Thought loops · Thought organization · Creativity enhancement · Humor enhancement · Language enhancement · Cognitive impairment · Confusion · Focus suppression · Thought disorganization · Thought deceleration
Analysis enhancement · Focus enhancement · Motivation enhancement · Information processing enhancement · Motivation suppression · Aesthetic enhancement · Cognitive dysphoria · Cognitive flexibility · Thought connectivity · Thought loops · Thought organization · Creativity enhancement · Humor enhancement · Language enhancement · Cognitive impairment · Confusion · Focus suppression · Thought disorganization · Thought deceleration
Anhedonia · Dysphoria · Emotional enhancement · Emotional lability · Empathy enhancement
Empathy enhancement
Sociability enhancement · Social connection · Flow state · Emotional susceptibility · Sociability suppression · Depersonalization · Derealization
Sociability suppression · Depersonalization · Derealization
Timeline
First effects emerge 15–45 minutes after oral ingestion: subtle mood lift, mild alertness increase, and slight peripheral stimulation.
Stimulation builds steadily. Thought acceleration, tachycardia, and appetite suppression become apparent. Nausea is possible during this phase.
Full stimulant profile: euphoria, focus enhancement, motivation, marked appetite suppression, tachycardia, bruxism. Oral onset is slower but peak may be more sustained than insufflated.
Diminishing euphoria with persistent wakefulness and cardiovascular stimulation. Compulsive redosing urge may be less acute than with insufflation due to the slower onset kinetics.
Slow return toward baseline. Residual wakefulness and restlessness outlast subjective stimulation. Sleep remains difficult.
Residual fatigue, low mood, appetite disturbance, and difficulty concentrating may persist for 8–16 hours after effects resolve. Given the prolonged plasma persistence documented for NEP, subclinical effects may outlast subjective awareness.
⚠ Do not drive or operate machinery until after a full night of restorative sleep following complete resolution of all subjective effects.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- Low
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- cocaine · amphetamine · methamphetamine
Toxicity
Acute toxicity
No lethal dose has been established for NEP in any species, and no therapeutic index exists.safety citation needed The most detailed acute toxicity case describes a patient who developed severe agitation, persecutory delusions, rapid heart rate, fever, muscle breakdown, acute kidney failure, metabolic acidosis, and coma after intranasal NEP use, requiring ICU admission and mechanical ventilation for three days.[4] Full recovery was achieved with supportive care.[4]
In mice, NEP produces mild temperature elevation at higher doses and reduced weight gain with repeated dosing.[7]
Heart and circulation
Rapid heart rate is confirmed in clinical reports.[4] High blood pressure is expected from norepinephrine reuptake inhibitor but has not been specifically documented for NEP. Heart rhythm disturbances have not been studied.safety citation needed
Kidney and muscle damage
Muscle breakdown and acute kidney failure are documented as NEP-attributable complications in a single case.[4] The mechanism is not established; heat-induced muscle damage and vasoconstriction reducing blood flow are plausible contributors.inferred
Temperature dysregulation
Fever is documented in the clinical case,[4] and mild temperature elevation occurs in mice at higher doses.[7]
Fatality data
NEP was detected in blood from 26 fatal and 2 non-fatal poisoning cases in Poland.[8] All fatalities involved multiple substances; NEP alone could not be isolated as cause of death. In a broader forensic series of 96 NPS-related deaths, synthetic cathinones were detected in 67% of cases, with alcohol co-detected in 27 cases (blood alcohol 0.6–3.6‰).[21]
No antidote exists for synthetic cathinone poisoning. Treatment is supportive, extrapolated from cocaine and amphetamine overdose protocols.[20] Muscle breakdown requires aggressive intravenous hydration; dialysis may be needed.[4]
Psychological risks
Severe agitation, persecutory delusions, and paranoia are documented in acute overdose.[4] In mice, withdrawal from repeated NEP produces increased aggression, impaired social behavior, and loss of the anxiety-reducing effect seen during acute exposure.[7] If these findings translate to humans, withdrawal may involve irritability, sociability suppression, and anxiety.
No data address long-term psychiatric outcomes. Given NEP's dopamine-selective mechanism and the paranoia documented in overdose, stimulant psychosis remains a risk during binge use or high-dose exposure.inferred
Tolerance & dependence
No human studies have assessed tolerance or dependence for NEP. Repeated administration in mice produces robust ΔFosB accumulation in the striatum — the most reliable molecular marker of addiction vulnerability — alongside depleted dopamine and elevated stress hormones during withdrawal.[7]
The structural precursor pentedrone maintains self-administration in rats and produces conditioned place preference.[22] Dopamine-selective cathinones carry the highest addiction liability among the three cathinone pharmacological groups.[13][14] NEP is characterized as having high abuse potential in the forensic literature.[6]
Tolerance half-life and full reset values have not been established.safety citation needed
Drug interactions
No NEP-specific interaction studies have been published. All assessments below are based on its pharmacological class.
Stimulant combinations
Co-use with other stimulants (Cocaine, amphetamines, other cathinones) carries additive cardiovascular risk — dangerous blood pressure elevation, rapid heart rate, overheating — and increases seizure potential.
Serotonergic combinations
Although NEP has minimal SERT activity, combinations with serotonin-active substances (MDMA, mephedrone) or serotonin reuptake inhibitors risk cardiovascular overstimulation and overheating through additive sympathomimetic effects. Combination with tramadol carries theoretical risk of serotonin syndrome.safety citation needed
Alcohol
Approximately 95% of synthetic cathinone users co-use alcohol.[23] In animal studies, alcohol-cathinone combinations potentiate brain toxicity approximately 2-fold.[23] Alcohol was co-detected in 27 of 96 NPS-related fatalities.[21]
Enzyme-mediated interactions
NEP's liver enzyme metabolism profile is uncharacterized.[16] If CYP2D6 is involved, drugs that inhibit this enzyme (fluoxetine, paroxetine, bupropion) could elevate NEP blood levels.inferred
Contraindications
No NEP-specific contraindication studies exist. The following are derived from its mechanism and class profile.
Heart conditions (high blood pressure, coronary artery disease, heart rhythm disorders, structural heart disease) represent absolute contraindications given confirmed rapid heart rate[4] and expected norepinephrine-driven cardiovascular stress. Kidney impairment is a relative contraindication given documented muscle breakdown and kidney failure.[4]
Psychotic disorders and bipolar disorder are relative contraindications, as dopamine stimulation may trigger or worsen psychotic episodes — supported by the persecutory delusions documented in the overdose case.[4] Seizure disorders carry theoretical risk from stimulant-mediated lowering of the seizure threshold.inferred
Pregnancy and breastfeeding are absolute contraindications: no reproductive safety data exist, and stimulant effects on blood flow and fetal development preclude safe use.safety citation needed
Concurrent MAOI use is an absolute contraindication due to risk of dangerous blood pressure crisis from accumulated catecholamines.inferred
Harm Reduction[edit]
Forms & Identification
NEP is typically sold as a white crystalline powder and is visually indistinguishable from dozens of other synthetic cathinones.[6] Standard clinical drug screens frequently fail to detect synthetic cathinones, returning false negatives even at high concentrations.[19] Reagent testing provides a first line of identification but cannot confirm purity or rule out contamination with other cathinones — only laboratory-grade analysis can do that.
The practical implication: any powder sold as NEP may contain a different cathinone with a different potency and risk profile. Start with the lowest plausible dose and wait for full onset before considering redosing.
Guidelines
- Test every batch with reagent kits before use; consider postal drug-checking services where available
- Weigh doses with a milligram-precision scale — never estimate by eye
- Choose oral administration over insufflation to reduce compulsive redosing urge and peak cardiovascular stress
- Set a firm dose limit and time limit before the session; write it down
- Stay hydrated but avoid overhydration — moderate, steady water intake
- Monitor body temperature; move to a cooler environment if overheating
- Have a sober companion present, especially at higher doses
- Avoid physical exertion in hot environments
- Do not combine with other stimulants, alcohol, or MAOIs
- Allow at least 24 hours between sessions to reduce cardiovascular and neurological strain
Set & Setting
NEP's dopamine-dominant profile means the balance between productive stimulation and anxious overstimulation is heavily influenced by environment and mental state. Physical settings with high temperatures or sustained physical activity increase the risk of overheating and muscle breakdown — both documented complications.[4]
The compulsive redosing urge is strongest with insufflation and in social or party settings. Having a predetermined dose limit and a sober companion reduces the likelihood of binge escalation. Solitary use removes external checks on escalation and delays recognition of medical emergencies.
Aftercare & integration. The stimulant comedown from NEP reflects temporary dopamine depletion. Low mood, fatigue, irritability, and difficulty concentrating are expected for 24–72 hours after use.
Prioritize sleep — avoid further stimulant use to "push through" fatigue. Eat nutrient-dense meals even if appetite is suppressed. Light physical activity and social contact can help restore baseline mood, but avoid intense exercise until body temperature, heart rate, and hydration have fully normalized.
If low mood persists beyond a week, or if the urge to redose dominates thinking between sessions, these are early signals of a developing use pattern that warrants professional support.
Recovery & Support
NEP's dopamine-selective mechanism and documented ΔFosB accumulation predict a dependence pattern characterized by strong cravings, compulsive redosing, and withdrawal marked by low mood and irritability.[7]
Recognizing the pattern is the first step: escalating doses, shortening intervals between sessions, continued use despite negative consequences, and inability to adhere to self-imposed limits. Professional support options include addiction counseling, cognitive behavioral therapy, and stimulant-specific recovery programs. SAMHSA's National Helpline (1-800-662-4357) provides free, confidential referrals in the United States.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
NEP emergencies are stimulant emergencies. Recognizing the line between uncomfortable and dangerous:
- Uncomfortable but manageable: anxiety, bruxism, mild nausea, elevated heart rate, restlessness
- Seek immediate help: chest pain, seizure, loss of consciousness, body temperature hot to the touch through clothing, persecutory delusions, severe confusion, inability to urinate (may signal kidney involvement)
Immediate steps:
- Call emergency services if any dangerous signs are present
- Move the person to a cool, quiet environment
- Remove excess clothing to aid cooling
- Offer small sips of water if conscious and alert
- Place in the recovery position if unconscious but breathing
- Do NOT restrain unless there is immediate danger of self-harm
- Do NOT induce vomiting
Tell the dispatcher: the substance name (NEP / synthetic cathinone), estimated amount and time of last dose, route of administration, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No reversal agent exists for synthetic cathinone overdose. All treatment is supportive.
Legal Status[edit]
NEP is not scheduled under the United Nations 1961 Single Convention on Narcotic Drugs or the 1971 Convention on Psychotropic Substances. Regulatory responses have been fragmented, with most jurisdictions relying on structural analog provisions or blanket psychoactive substance legislation rather than specific scheduling.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not specifically scheduled (as of April 2026) | Not included in the June 2022 Schedule I placement of NEH and five other cathinones.[9] Prosecution possible under the Federal Analogue Act. DEA-commissioned abuse liability study published 2025[5] |
| United Kingdom | Controlled under Psychoactive Substances Act 2016 | Broadly banned since 26 May 2016. Not specifically named in the Misuse of Drugs Act 1971 |
| European Union | Subject to EU Early Warning System monitoring | EUDA published formal initial report in June 2025.[3] Individual member state scheduling varies |
| Sweden | Hälsofarlig vara (potentially harmful substance) | Controlled under Swedish public health legislationcitation needed |
| Japan | Designated stimulant analog | Controlled as a potentially harmful substancecitation needed |
| China | Controlled | Regulated under non-medical psychoactive substance provisionscitation needed |
Analog act considerations
In the United States, the Federal Analogue Act (21 U.S.C. § 813) allows prosecution for distribution or possession of substances substantially similar in chemical structure or pharmacological effect to Schedule I or II controlled substances, when intended for human consumption. NEP's structural similarity to N-ethylhexedrone (Schedule I since June 2022[9]) and published behavioral data confirming cocaine/methamphetamine-like effects[5] provide a strong basis for analog act prosecution.
references
- [1] ^abSimmler LD, Rickli A, Hoener MC, Liechti ME (2014) Monoamine transporter and receptor interaction profiles of a new series of designer cathinones — Neuropharmacology doi:10.1016/j.neuropharm.2013.11.008
- [2] ^abcKolaczynska KE, Thomann J, Hoener MC, Liechti ME (2021) The Pharmacological Profile of Second Generation Pyrovalerone Cathinones and Related Cathinone Derivative. — International journal of molecular sciences doi:10.3390/ijms22158277
- [3]
- [4]
- [5] ^abcdGatch MB, Hill RD, Shetty RA, et al. (2025) Locomotor stimulant and drug discrimination effects of five synthetic cathinones in rodents — Pharmacology, biochemistry, and behavior doi:10.1016/j.pbb.2025.174100
- [6]